We are reporting from the 2020 ASCO Virtual Scientic Program!
We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Drs Brian Rini and Christopher Sweeney on some significant data being presented in genitourinary cancers, as well as Dr Roy Herbst on some practice-changing lung cancer studies.
Welcome to OncLive News Network! I’m Gina Columbus.
Findings from the phase 3 KEYNOTE-204 trial showed that treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma.
In Waldenstrom macroglobulnemia, results of the phase 3 ASPEN trial showed that zanubrutinib was associated with a higher complete response or very good partial response rate, as well as clinically meaningful advantages in safety and tolerability compared with ibrutinib in this patient population.
Over half of patients with PIK3CA-positive, HR-positive/HER2-negative advanced breast cancer who had prior treatment with a CDK4/6 inhibitor plus an aromatase inhibitor were alive without disease progression 6 months after starting treatment with alpelisib plus fulvestrant, as seen in findings from the phase 2 BYLieve trial.
In updated findings from part 1 of the phase 3 CheckMate-227 trial, patients with advanced non-small cell lung cancer and tumor PD-L1 expression 1% or greater or less than 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.
Additionally, results from the CheckMate 9LA trial suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population, as the trial showed a superiority in overall survival with the immunotherapy combination versus chemotherapy alone.
In triple-negative breast cancer, pembrolizumab in combination with several chemotherapy partners led to a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally recurrent, inoperable, or metastatic disease tumors expressed PD-L1 with a combined positive score of 10 or higher, according to results of the phase 3 KEYNOTE-355 trial.
The DREAMM clinical trial program continues to highlight the antibody-drug conjugate belantamab mafodiotin in multiple myeloma. In DREAMM-2, single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma. In the DREAMM-6 study, belantamab mafodotin in combination with bortezomib and dexamethasone demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.
Also in multiple myeloma, the BCMA-targeting CAR T-cell therapy idecabtagene vicleucel induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma in data from the pivotal phase 2 KarMMA trial. The overall response rate with ide-cel was 73%, including a complete response rate of 33%. The median duration of response was 10.7 months, and the median progression-free survival was 8.8 months.
First-in-human findings from the phase 1 ALPHA study demonstrated that the allogeneic chimeric antigen receptor T cell therapy ALLO-501, when paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma.
Updated results exploring the novel KRAS G12C inhibitor AMG 510 demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non—small cell lung cancer and colorectal cancer.
In prostate cancer, results of the phase 3 HERO trial relugolix demonstrated superiority over leuprolide acetate in sustained testosterone suppression through 48 weeks in patients with advanced prostate cancer.
In cohort findings of an interim analysis of the DESTINY-Lung01 trial, fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non—small cell lung cancer.
In ovarian cancer, mirvetuximab soravtansine in combination with bevacizumab demonstrated encouraging overall response rates in patients with platinum-agnostic ovarian cancer regardless of platinum status with a favorable tolerability profile.
Updated survival data of the phase 2 portion of the AVANOVA trial showed that clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.
That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location at the 2020 ASCO Virtual Scientific Program, when we sit down with Dr. Keith Flaherty on some pivotal studies being presented in melanoma, as well as ASCO president Dr Skip Burris on takeaways from this year’s meeting.
Thank you for watching OncLive News Network! I’m Gina Columbus.